Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase IIa clinical trials for the treatment of cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase IIa clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Phone+972-4-9028100
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/8/2019 (Estimated)
OptionableOptionable
Protalix Biotherapeutics (NYSEAMERICAN:PLX) Frequently Asked Questions
What is Protalix Biotherapeutics' stock symbol?
Protalix Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PLX."
How were Protalix Biotherapeutics' earnings last quarter?
Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) announced its quarterly earnings results on Monday, March, 18th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.05) by $0.12. The firm had revenue of $27.02 million for the quarter, compared to analyst estimates of $10.45 million. View Protalix Biotherapeutics' Earnings History.
When is Protalix Biotherapeutics' next earnings date?
What price target have analysts set for PLX?
1 Wall Street analysts have issued 1-year price objectives for Protalix Biotherapeutics' shares. Their predictions range from $3.00 to $3.00. On average, they anticipate Protalix Biotherapeutics' share price to reach $3.00 in the next year. This suggests a possible upside of 553.6% from the stock's current price. View Analyst Price Targets for Protalix Biotherapeutics.
What is the consensus analysts' recommendation for Protalix Biotherapeutics?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protalix Biotherapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Protalix Biotherapeutics.
What are Wall Street analysts saying about Protalix Biotherapeutics stock?
Here are some recent quotes from research analysts about Protalix Biotherapeutics stock:
- 1. According to Zacks Investment Research, "Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx(R). Protalix's unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights. " (3/21/2019)
- 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. Our model yields an rNPV of $280M for PRX-102 using a 15% discount rate and 75% probability of approval, accounting for the receipt of royalties on PRX-102 sales globally. We also ascribe an rNPV of $230M to alidornase alfa, a $100M rNPV for $50M rNPV for OPRX-106, translating into a price per share of $4.00. This assumes 149M shares outstanding as of end-2019." (12/13/2018)
Has Protalix Biotherapeutics been receiving favorable news coverage?
News coverage about PLX stock has trended neutral on Sunday, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Protalix Biotherapeutics earned a news impact score of 0.2 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an effect on the stock's share price in the next few days.
Are investors shorting Protalix Biotherapeutics?
Protalix Biotherapeutics saw a increase in short interest during the month of February. As of February 28th, there was short interest totalling 2,828,591 shares, an increase of 1.3% from the February 15th total of 2,864,722 shares. Based on an average daily volume of 504,993 shares, the days-to-cover ratio is currently 5.6 days. Currently, 2.1% of the shares of the company are short sold. View Protalix Biotherapeutics' Current Options Chain.
Who are some of Protalix Biotherapeutics' key competitors?
Some companies that are related to Protalix Biotherapeutics include Enochian Biosciences (ENOB), Monash IVF Group (MVF), Emblem (EMC), Horizon Discovery Group (HZD), IMV (IMV), Kodiak Sciences (KOD), BELLUS Health (BLU), 22nd Century Group (XXII), BioTime (BTX), BioTime (BTX), ProMetic Life Sciences (PLI), MediGene (MDG1), CorMedix (CRMD), Pfenex (PFNX) and CorMedix (CRMD).
What other stocks do shareholders of Protalix Biotherapeutics own?
Who are Protalix Biotherapeutics' key executives?
Protalix Biotherapeutics' management team includes the folowing people:
- Mr. Moshe Manor, CEO, Pres & Director (Age 63)
- Dr. Yoseph Shaaltiel, Founder and Exec. VP R&D (Age 65)
- Mr. Yossi Maimon CPA, MBA, CFO, VP, Treasurer & Sec. (Age 48)
- Dr. Einat Brill-Almon, Sr. VP of Product Devel. (Age 59)
- Mr. Yaron Naos, Sr. VP of Operations (Age 56)
Who are Protalix Biotherapeutics' major shareholders?
Protalix Biotherapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.06%). Company insiders that own Protalix Biotherapeutics stock include Moshe Manor, Randall Peel Boyd and Steve Dabner. View Institutional Ownership Trends for Protalix Biotherapeutics.
Which institutional investors are buying Protalix Biotherapeutics stock?
PLX stock was acquired by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought Protalix Biotherapeutics stock in the last two years include Moshe Manor, Randall Peel Boyd and Steve Dabner. View Insider Buying and Selling for Protalix Biotherapeutics.
How do I buy shares of Protalix Biotherapeutics?
Shares of PLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Protalix Biotherapeutics' stock price today?
One share of PLX stock can currently be purchased for approximately $0.4590.
How big of a company is Protalix Biotherapeutics?
Protalix Biotherapeutics has a market capitalization of $68.11 million.
What is Protalix Biotherapeutics' official website?
How can I contact Protalix Biotherapeutics?
Protalix Biotherapeutics' mailing address is 2 Snunit St, Science Park, Pob 455, KARMIEL, 20100, Israel. The company can be reached via phone at +972-4-9028100.
MarketBeat Community Rating for Protalix Biotherapeutics (NYSEAMERICAN PLX)
MarketBeat's community ratings are surveys of what our community members think about Protalix Biotherapeutics and other stocks. Vote "Outperform" if you believe PLX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PLX will underperform the S&P 500 over the long term. You may vote once every thirty days.
